Similar findings have also been reported in other ROS1 and ALK lung cancer cohorts, further supporting the notion that ROS1‐rearranged and ALK‐rearranged NSCLCs are specifically associated with an elevated risk of thromboembolic events.2, 3, 4, 5, 6, 7. This evidence concerns the gene ROS1 and lung cancer.